Latest IR information
IR News
- 2026.06.09
- SymBio Announces First Patient In (FPI) in NIH-led Trial of IV BCV for Progressive Multifocal Leukoencephalopathy (PML)
- 2026.06.02
- SymBio Presents Data on the Efficacy of Brincidofovir (BCV) in Combination with an Immune Checkpoint Inhibitor for Treatment of Epstein-Barr Virus-Associated Gastric Carcinoma at the American Society of Clinical Oncology (ASCO 2026)
- 2026.06.01
- Notice Regarding the Monthly Exercise Status of the 58th and 66th Stock Acquisition Rights (with Exercise Price Adjustment Clause) Issued through Third-Party Allotment
- 2026.05.28
- SymBio Secures European Patent for Use of IV BCV for Adenovirus Infection Strengthening Exclusive Patent Rights for IV BCV in Japan, the U.S., and Europe
- 2026.05.18
- SymBio Establishes Stable Supply Framework for Ultra-High-Sensitive (Pico-Level) Immunochromatography System